Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16806
Title: Treatment of ALK-rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context
Austin Authors: Itchins, M;Chia, Puey Ling ;Hayes, SA;Howell, VM;Gill, AJ;Cooper, WA;John, Thomas ;Mitchell, Paul L R ;Millward, M;Clarke, SJ;Solomon, B;Pavlakis, N
Affiliation: Bill Walsh Translational Research Laboratory, Kolling Institute Medical Institute of Research, Royal North Shore Hospital, St Leonards, New South Wales, Australia
Sydney Medical School, Northern Clinical School, University of Sydney, Sydney, New South Wales, Australia
Northern Cancer Institute, St Leonards, New South Wales, Australia
Medical Oncology Unit, Olivia Newton John Cancer and Wellness Centre, Austin Health, Heidelberg, Victoria, Australia
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Department of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia
Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards, New South Wales, Australia
Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
School of Medicine, Western Sydney University, Sydney, New South Wales, Australia
School of Medicine, University of Western Australia, Perth, Western Australia, Australia
Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
Linear Clinical Research, Nedlands, Western Australia, Australia
Department of Medical Oncology, Royal North Shore Hospital, St Leonards, New South Wales, Australia
Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia
Issue Date: Aug-2017
Publication information: Asia-Pacific Journal of Clinical Oncology 2017; 13 (Supp 3): 3-13
Abstract: Since the identification of anaplastic lymphoma kinase (ALK) gene rearrangements in non-small cell lung cancer (NSCLC) in 2005, the treatment of ALK-rearranged NSCLC (ALK+ NSCLC) has evolved at a rapid pace. This molecularly distinct subset of NSCLC has uniquely important biology, clinicopathologic features and mechanisms of drug resistance which impact on the choice of treatment for a patient with this disease. There are multiple ALK tyrosine kinase inhibitors now available in clinical practice with efficacy data continuing to emerge and guide the optimal treatment algorithm. A detailed search of medical databases and clinical trial registries was conducted to capture all relevant articles on this topic enabling an updated detailed overview of the landscape of management of ALK-rearranged NSCLC.
URI: http://ahro.austin.org.au/austinjspui/handle/1/16806
DOI: 10.1111/ajco.12754
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/28795492
Type: Journal Article
Subjects: ALK
Non-small cell lung cancer
Resistance
Survival
Tyrosine kinase inhibitors
Appears in Collections:Journal articles

Show full item record

Page view(s)

2
checked on Dec 1, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.